[Chinese expert consensus on the diagnosis and treatment of Burkitt lymphoma (2026)].

Burkitt lymphoma accounts for less than 5% of adult lymphomas and is clinically highly aggressive. Despite improved prognosis with dose-intensive therapy, Burkitt lymphoma remains a specific area of clinical and biological research, and there are currently no consensus recommendations regarding the diagnosis, treatment, and prognostic factors in adult patients. In order to strengthen the understanding of Burkitt lymphoma in our country, improve the diagnosis and treatment level, and help promote multi-center clinical research, the Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association and Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO) organized relevant experts to discuss and form this consensus on the basis of the relevant consensus on the diagnosis and treatment of Burkitt lymphoma, combined with the latest research progress both domestically and internationally.